U.S., Dec. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07303283) titled 'Becotatug Vedotin as Adjuvant Therapy For High-risk Nasopharyngeal Carcinoma' on Dec. 11.
Brief Summary: This is a phase 2, multicentre, open-label, randomised, controlled trial with a parallel-group design. The study aims to evaluate the efficacy and safety of Becotatug Vedotin as an adjuvant therapy in patients with high-risk locoregionally advanced nasopharyngeal carcinoma (NPC).
Study Start Date: March 01, 2026
Study Type: INTERVENTIONAL
Condition:
Nasopharyngeal Carcinoma (NPC)
Intervention:
DRUG: Becotatug Vedotin
This group will receive Becotatug Vedotin at a dose of 2.3 mg/kg on day 1 of each 3-week cycle for a total ...